+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06774872

Comparing DoravirineLamivudine and DolutegravirLamivudine Dual Therapies to Maintain Viral Control in Adults Living with HIV-1 on Stable Triple Therapy

Led by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Updated on 2025-06-11

408

Participants Needed

1

Research Sites

73 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the ability of two dual-drug regimens, DoravirineLamivudine DOR3TC and DolutegravirLamivudine DTG3TC, to maintain virological success at 48 weeks in people living with HIV who have a suppressed viral load under a three-drug regimen. The goal is to determine whether DOR3TC is not less effective than DTG3TC in keeping HIV under control. This phase 2 trial addresses the need for dual therapies that avoid integrase inhibitors and boosted protease inhibitors, especially for patients with past drug intolerances or resistance. Participants will be randomly assigned to one of two groups. One group will receive doravirine 100 mg plus lamivudine 300 mg daily, while the other will receive a fixed combination of dolutegravir 50 mg and lamivudine 300 mg daily. Both treatments follow approved dosages. The study compares these dual therapies over 48 weeks to assess how well they maintain viral suppression. During the study, participants will be monitored for virological efficacy through plasma viral load measurements, with virological success defined as no confirmed viral rebound. Researchers will collect data up to week 48 to evaluate maintenance of viral control. Safety, tolerance, and resistance will also be assessed. Participation involves regular visits and adherence to the assigned treatment, with the total study duration covering at least 48 weeks.

CONDITIONS

Brief Title

Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

Research Team

Y

Yasmine DUDOIT

R

Romain PALICH, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here